SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Jae Park, M.D., acting Chief of Cellular Therapeutics at Memorial Sloan Kettering Cancer Center in New York, to its Scientific Advisory Board (SAB). Dr. Park, widely recognized as one of the world experts in cell therapies, is the leading principal investigator of several clinical trials in patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia.
“We are honored to welcome Dr. Park to our Scientific Advisory Board,” said Rafael Amado, M.D., Executive Vice President of Research & Development and Chief Medical Officer of Allogene. “Dr. Park’s groundbreaking research and experience treating patients with CAR T and other novel immunotherapies will help us maintain our leadership postion as we advance our platform for patients with blood cancers and solid tumors.”
Dr. Park is Associate Attending Physician in the Division of Hematologic Oncology, Leukemia Service, a Director of Adult Acute Lymphoblastic Leukemia Program and the Acting Chief of Cellular Therapeutics Service at Memorial Sloan Kettering Cancer Center in New York, New York. Dr. Park received his medical degree from the Johns Hopkins School of Medicine, and completed an internal medicine residency at Massachusetts General Hospital and a hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center. Dr. Park has written numerous peer-reviewed articles appearing in New England Journal of Medicine, Science Translational Medicine, Blood, Cancer Discovery and Journal of Clinical Oncology. His research – which focuses on translating and establishing novel targeted and immunotherapies for patients with hematologic malignancies – has been recognized and funded by the The American Society of Hematology, The American Association for Cancer Research, The American Society of Clinical Oncology, The Leukemia and Lymphoma Society, The Geoffrey Beene Research Foundation, and The National Comprehensive Cancer Network.
The Allogene SAB comprises experts across oncology, immunology, cell therapy, and drug discovery and development. Dr. Park joins existing SAB members, Chair Ton Schumacher, Ph.D., Donald B. Kohn, M.D., Malcom K. Brenner, M.D., Ph.D., Matthew Porteus, M.D., Ph.D., Owen Witte, M.D., Stephan Grupp, M.D., Ph.D., Stephen J. Forman, M.D., Thomas F. Gajewski, M.D., Ph.D., and Wendell Lim, Ph.D.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T therapies for cancer and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the SEC, including without limitation in its Form 10-Q for the quarter ended June 30, 2021. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com
